BioNTech SE (BNTX) Consolidated Net Income (2018 - 2025)
BioNTech SE (BNTX) posted Consolidated Net Income of -$174.4 million for Q4 2025, down 290.98% sequentially from $91.3 million in Q3 2025, and down 147.59% YoY from $366.4 million in Q4 2024.
BioNTech SE (BNTX) Consolidated Net Income (2018 - 2025) Analysis & Trends
BioNTech SE has reported Consolidated Net Income for 8 years, with the latest figure at -$174.4 million in Q4 2025.
- Quarterly Consolidated Net Income fell 147.59% year-over-year to -$174.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.1 billion (down 41.52% YoY) and the FY2025 annual result came in at -$1.3 billion, down 80.55% from the prior year.
- Consolidated Net Income slipped to -$174.4 million in Q4 2025 per BNTX's latest filing, from $91.3 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $7.2 billion in Q3 2021 and troughed at -$865.6 million in Q2 2024.
- A 5-year average of $2.0 billion and a median of $650.4 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2021 and 2025: Consolidated Net Income surged 13561718996.32% in 2021, then sank 147.59% in 2025.
- Over 5 years, Consolidated Net Income stood at $7.2 billion in 2021, then slumped by 42.08% to $4.1 billion in 2022, then tumbled by 77.48% to $934.5 million in 2023, then plunged by 60.79% to $366.4 million in 2024, then tumbled by 147.59% to -$174.4 million in 2025.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$174.4 million, $91.3 million, and -$474.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -174.37 Mn |
| Sep 30, 2025 | 91.30 Mn |
| Jun 30, 2025 | -474.06 Mn |
| Mar 31, 2025 | -499.65 Mn |
| Dec 31, 2024 | 366.42 Mn |
| Sep 30, 2024 | 131.02 Mn |
| Jun 30, 2024 | -865.60 Mn |
| Mar 31, 2024 | -378.60 Mn |
| Dec 31, 2023 | 934.45 Mn |
| Sep 30, 2023 | 320.26 Mn |
| Jun 30, 2023 | -690.38 Mn |
| Mar 31, 2023 | 980.18 Mn |
| Dec 31, 2022 | 4.15 Bn |
| Sep 30, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.17 Bn |
| Mar 31, 2022 | 7.11 Bn |
| Dec 31, 2021 | 7.16 Bn |
| Sep 30, 2021 | 7.22 Bn |
| Jun 30, 2021 | 6.33 Bn |
| Mar 31, 2021 | 2.60 Bn |